These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 37837546)

  • 1. The role of the PLGF in the prediction of the outcome in pregnancies with a small for gestational age fetus.
    Souka AP; Antsaklis P; Tassias K; Chatziioannou MA; Papamihail M; Daskalakis G
    Arch Gynecol Obstet; 2024 Jul; 310(1):237-243. PubMed ID: 37837546
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of the PLGF in the management of pregnancies complicated with fetal microsomia.
    Souka AP; Chatziioannou MI; Pegkou A; Antsaklis P; Daskalakis G
    Arch Gynecol Obstet; 2024 Apr; 309(4):1369-1376. PubMed ID: 36977917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of small for gestational age neonates: screening by maternal factors, fetal biometry, and biomarkers at 35-37 weeks' gestation.
    Ciobanu A; Rouvali A; Syngelaki A; Akolekar R; Nicolaides KH
    Am J Obstet Gynecol; 2019 May; 220(5):486.e1-486.e11. PubMed ID: 30707967
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of sFlt-1/PlGF ratio and feto-maternal Doppler for the prediction of adverse perinatal outcome in late-onset pre-eclampsia.
    Graupner O; Karge A; Flechsenhar S; Seiler A; Haller B; Ortiz JU; Lobmaier SM; Axt-Fliedner R; Enzensberger C; Abel K; Kuschel B
    Arch Gynecol Obstet; 2020 Feb; 301(2):375-385. PubMed ID: 31734756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biophysical and biochemical markers at 30-34 weeks' gestation in the prediction of adverse perinatal outcome.
    Valiño N; Giunta G; Gallo DM; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Feb; 47(2):194-202. PubMed ID: 26094952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 30-34 weeks.
    Bakalis S; Peeva G; Gonzalez R; Poon LC; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Oct; 46(4):446-51. PubMed ID: 25826154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Second-trimester contingent screening for small-for-gestational-age neonate.
    Nowacka U; Papastefanou I; Bouariu A; Syngelaki A; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2022 Feb; 59(2):177-184. PubMed ID: 34214232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.
    Chaiworapongsa T; Romero R; Whitten AE; Korzeniewski SJ; Chaemsaithong P; Hernandez-Andrade E; Yeo L; Hassan SS
    J Matern Fetal Neonatal Med; 2016; 29(8):1214-28. PubMed ID: 26303962
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting delivery of a small-for-gestational-age infant and adverse perinatal outcome in women with suspected pre-eclampsia.
    Griffin M; Seed PT; Duckworth S; North R; Myers J; Mackillop L; Simpson N; Waugh J; Anumba D; Kenny LC; Redman CWG; Shennan AH; Chappell LC
    Ultrasound Obstet Gynecol; 2018 Mar; 51(3):387-395. PubMed ID: 28401605
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Placental growth factor as an indicator of fetal growth restriction in late-onset small-for-gestational age pregnancies.
    Anderson N; De Laat M; Benton S; von Dadelszen P; McCowan L
    Aust N Z J Obstet Gynaecol; 2019 Feb; 59(1):89-95. PubMed ID: 29851029
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biophysical and biochemical markers at 35-37 weeks' gestation in the prediction of adverse perinatal outcome.
    Valiño N; Giunta G; Gallo DM; Akolekar R; Nicolaides KH
    Ultrasound Obstet Gynecol; 2016 Feb; 47(2):203-9. PubMed ID: 26224608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Placental growth factor and fetoplacental Doppler indices in combination predict preterm birth reliably in pregnancies complicated by fetal growth restriction.
    Hong J; Crawford K; Cavanagh E; da Silva Costa F; Kumar S
    Ultrasound Obstet Gynecol; 2024 May; 63(5):635-643. PubMed ID: 37820083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Routine first-trimester combined screening for pre-eclampsia: pregnancy-associated plasma protein-A or placental growth factor?
    Noël L; Guy GP; Jones S; Forenc K; Buck E; Papageorghiou AT; Thilaganathan B
    Ultrasound Obstet Gynecol; 2021 Oct; 58(4):540-545. PubMed ID: 33998078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ophthalmic artery Doppler and biomarkers of impaired placentation at 36 weeks' gestation in pregnancies with small fetuses.
    Arechvo A; Wright A; Nobile Recalde A; Liandro R; Charakida M; Nicolaides KH
    Ultrasound Obstet Gynecol; 2024 Mar; 63(3):358-364. PubMed ID: 37902727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ten-year experience of protocol-based management of small-for-gestational-age fetuses: perinatal outcome in late-pregnancy cases diagnosed after 32 weeks.
    Meler E; Mazarico E; Eixarch E; Gonzalez A; Peguero A; Martinez J; Boada D; Vellvé K; Gomez-Roig MD; Gratacós E; Figueras F
    Ultrasound Obstet Gynecol; 2021 Jan; 57(1):62-69. PubMed ID: 33159370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prediction of small-for-gestational-age neonates: screening by placental growth factor and soluble fms-like tyrosine kinase-1 at 35-37 weeks.
    Fadigas C; Peeva G; Mendez O; Poon LC; Nicolaides KH
    Ultrasound Obstet Gynecol; 2015 Aug; 46(2):191-7. PubMed ID: 25825848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of placental, fetal and maternal cardiovascular markers in predicting adverse outcome in women with suspected or confirmed pre-eclampsia.
    Reddy M; Palmer K; Rolnik DL; Wallace EM; Mol BW; Da Silva Costa F
    Ultrasound Obstet Gynecol; 2022 May; 59(5):596-605. PubMed ID: 34985800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Screening for pre-eclampsia at 11-13 weeks' gestation: use of pregnancy-associated plasma protein-A, placental growth factor or both.
    Mazer Zumaeta A; Wright A; Syngelaki A; Maritsa VA; Da Silva AB; Nicolaides KH
    Ultrasound Obstet Gynecol; 2020 Sep; 56(3):400-407. PubMed ID: 32441401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention.
    Poon LC; Shennan A; Hyett JA; Kapur A; Hadar E; Divakar H; McAuliffe F; da Silva Costa F; von Dadelszen P; McIntyre HD; Kihara AB; Di Renzo GC; Romero R; D'Alton M; Berghella V; Nicolaides KH; Hod M
    Int J Gynaecol Obstet; 2019 May; 145 Suppl 1(Suppl 1):1-33. PubMed ID: 31111484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Maternal serum placental growth factor (PlGF) in small for gestational age pregnancy at 11(+0) to 13(+6) weeks of gestation.
    Poon LC; Zaragoza E; Akolekar R; Anagnostopoulos E; Nicolaides KH
    Prenat Diagn; 2008 Dec; 28(12):1110-5. PubMed ID: 19003787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.